Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

479
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
479

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the Role of Chemotherapy in Addition to Radiotherapy for High-Risk Merkel Cell Carcinoma.

Medical sciences (Basel, Switzerland)·2026
Same author

Suction Impact on Chest Drain Duration After Lung Resection: A Study Using Digital Drainage Systems.

Journal of clinical medicine·2026
Same author

Optimal Duration of Adjuvant Platinum-Etoposide in High-Risk Merkel Cell Carcinoma.

Medicina (Kaunas, Lithuania)·2026
Same author

Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC.

Medical sciences (Basel, Switzerland)·2026
Same author

Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC.

Frontiers in molecular biosciences·2026
Same author

Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy.

Life (Basel, Switzerland)·2026
Same journal

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same journal

Surgical and Transcatheter Approach of a Failed Mitral Valve Repair: A Comprehensive Review on Selecting the Most Suitable Approach.

Journal of clinical medicine·2026
Same journal

Hybrid Metaheuristic Feature Selection for Breast Cancer Detection in Digital Mammography: A Feasibility Study with Nested Validation, Benchmarking, and External Stress Testing.

Journal of clinical medicine·2026
Same journal

Identity Transformation and the Role of Accountability in Recovery from Problematic Pornography Use: A Phenomenological-Hermeneutical Study.

Journal of clinical medicine·2026
Same journal

Does Early Surgical Treatment in Degenerative Cervical Myelopathy Have a Favorable Clinical Outcome and Impact on Quality of Life?

Journal of clinical medicine·2026
Same journal

Shear Wave Elastography in Musculoskeletal Imaging: A Narrative Review.

Journal of clinical medicine·2026
See all related articles

Related Experiment Video

Updated: May 21, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Real-World Data on Osimertinib-Associated Cardiac Toxicity.

Abed Agbarya1, Ari Raphael2, Hadas Gantz Sorotsky3,4

  • 1Oncology Department, Bnai Zion Medical Centre, Haifa 31048, Israel.

Journal of Clinical Medicine
|March 17, 2025
PubMed
Summary
This summary is machine-generated.

Osimertinib, an EGFR-TKI for lung cancer, can cause cardiotoxicity, especially in patients with existing heart conditions. Early monitoring and management are crucial for safe treatment.

Keywords:
EGFR mutationscardiac toxicitynon-small cell lung cancerosimertinibreal-world data

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

1.8K

Related Experiment Videos

Last Updated: May 21, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

1.8K

Area of Science:

  • Oncology
  • Cardiology

Background:

  • Lung cancer is a leading global cause of cancer death.
  • Epidermal growth factor receptor (EGFR) mutations occur in 17-39% of non-small cell lung cancer (NSCLC).
  • Osimertinib is a key EGFR tyrosine kinase inhibitor (EGFR-TKI) for EGFR-mutated NSCLC, but its cardiac risks are not fully understood.

Purpose of the Study:

  • To investigate the incidence and characteristics of osimertinib-related cardiotoxicity in EGFR-mutated NSCLC patients.
  • To identify risk factors and outcomes associated with osimertinib-induced cardiac adverse events.

Main Methods:

  • Retrospective analysis of a multi-center registry data.
  • Inclusion criteria: NSCLC patients with EGFR mutations receiving first-line osimertinib (Dec 2018 - Apr 2024).
  • Cardiotoxicity defined as reduced ejection fraction (EF) and/or cardiac death.

Main Results:

  • 17 patients evaluated; most had smoking history.
  • Cardiac toxicity emerged 1-28 months post-initiation; 70.59% within 6 months.
  • 14 patients showed EF recovery, but not to baseline; high prevalence of comorbidities (heart failure, hypertension).

Conclusions:

  • Osimertinib-associated cardiotoxicity is a significant concern, particularly in patients with comorbidities.
  • Close monitoring, early intervention, and personalized management are essential.
  • Rechallenge may be possible for mild toxicity; severe/persistent cases warrant exclusion from osimertinib.